Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world NGS-based prediction of luspatercept efficacy in myeloid neoplasm-related anemia
ChiCTR2500107518Phase 4Recruiting
- Sponsor
- Beijing No. 6 Hospital
- Start
- Jan 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of luspatercept in myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), polycythemia vera (PV) and 4 more (2 arms), sponsored by Beijing No. 6 Hospital. Primary endpoints: Blood routine indicators and Red blood cell transfusion. Started Jan 2025; status: recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)myeloproliferative disorder (MPD)polycythemia vera (PV)thrombocythemiaprimary myelofibrosis (PMF)
Beyond the preview
Go deeper on ChiCTR2500107518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107518.